Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Dimerix Ltd

DXB.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.17

▲ +2.08%

Market Cap $104.23M · Vol 286.20K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$104.23M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

31.25

Momentum

Beta

0.46

vs Market

52W High

$0.47

61.83% below

52W Low

$0.11

53.20% above

Volume

286.20K

Avg 1.04M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

77.77%

Public shares

Shariah Compliance8 STANDARDS

✗ Dimerix Ltd (DXB.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DXB.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.00%

-18.33%

+28.95%

-36.36%

YTD

-55.45%

-53.33%

+323.11%

-10.95%

Financials & Valuation

TTM · Annual

Total Revenue	$4.83M
Net Income	$-20,627,794.00
Revenue Growth (YoY)	-14.21%
Gross Margin	100.00%
Operating Margin	-494.15%
Net Profit Margin	-427.26%
ROE	N/A
ROA · ROIC	-46.14% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	17.64
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	600.40M

Technical Indicators

50-Day SMA	$0.19
200-Day SMA	$0.25
RSI (14)	31.25
Beta	0.46
52-Week High	$0.47
52-Week Low	$0.11

Volume Today	286.20K
Avg Daily Volume (30D)	1.04M
Relative Volume	0.27x
Volatility (10D)	35.48
Volatility (30D)	54.21
Free Float	77.77%

Analyst Consensus

N/A

Current Price $0.17

Mean Target N/A

52W Low$0.11 52W High$0.47

Current

Target

$0.11 $0.47

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001S9Z6Y8

ISINAU000000DXB7

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.